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A 66-year-old man with symptomatic hypertensive episodes was found to have a 9-mm adrenal mass
and elevated metanephrine levels. He was scheduled for an adrenalectomy for suspected pheochro-
mocytoma. Subsequent workup revealed a large bladder mass which was found to be a paraganglioma.
There is no consensus on what should be considered the standard management of primary bladder
paraganglioma, including surgical technique, assessment of malignancy, and appropriate follow-up,
owing to the rarity of the diagnosis.
 2014 Elsevier Inc. All rights reserved.Introduction
Paragangliomas are rare growths of chromafﬁn tissue derived
from neural crest cells, histologically identical to pheochromocy-
toma but located at extra-adrenal sites.1 Only 6% of paragangliomas
are located in the bladder, and only 0.06% of all bladder neoplasms
are paragangliomas.2 Bladder paragangliomas are three times more
common in females than males and primarily present in the second
and third decades of life.3 Here we discuss the case of an unusual
presentation of a bladder paraganglioma.Case presentation
A 66-year-old man with a 15-year history of hypertension
presented to an ambulatory clinic with a chief complaint of
episodic hypertension with systolic pressures up to 250 mm Hg.
These episodes began with a sense of fecal urgency and urinary
tingling once or twice per day. He then developed bulging of his
veins and sensations of tingling, ﬂushing, and pressure throughout
his body.
He underwent workup for pheochromocytoma, and was found to
have elevated metanephrine and normetanephrine levels. Oral phe-
noxybenzamine treatment was initiated, which decreased the
severity and frequency of his hypertensive episodes. AdrenalBY-NC-ND license (http://
0-614-3695.
ll rights reserved.computed tomography at that time revealed a 9-mm left-sided ad-
renal nodule (Fig. 1). This nodule appeared consistent with an adrenal
adenoma, given its small size and radiodensity of 2 Hounsﬁeld units
(HU; nearly all lesions under 10 HUs on noncontrast imaging are
adenomas). However, because of his symptoms and elevated meta-
nephrine levels, the adrenal nodule was assumed to be a pheochro-
mocytoma and he was scheduled for adrenalectomy. However,
subsequent conﬁrmatory metaiodobenzylguanidine (MIBG) scintig-
raphywas negative and as the imaging suggested that the nodulewas
an adrenal adenoma, he did not undergo the procedure. He also did
not undergo metabolic workup for hyperaldosteronism or hyper-
cortisolism, as his metanephrines were elevated and this is only
mandatory in patients with masses >1 cm.
Subsequently, computed tomography angiography of the
abdomen and pelvis was performed. This demonstrated a 2.6-cm
heterogeneously enhancing bladder mass suspicious for a para-
ganglioma (Fig. 2). The patient underwent transurethral resection
of the tumor, but complete resection was not possible due to the
lesion’s size, location, and branched arterial vascularization. Pa-
thology revealed a paraganglioma involving themuscularis propria.
One month later, he underwent partial cystectomy and bilateral
pelvic lymphadenectomy. Frozen sections for margins were nega-
tive, and the ﬁnal pathology report revealed a 2.5-cm para-
ganglioma (Fig. 3). The 26 sampled nodes were negative for tumor,
and his phenoxybenzamine blockadewas discontinued. At his most
recent follow-up 16 weeks after surgery, the patient has had
complete resolution of his hypertensive episodes, has normal urine
metanephrine and normetanehprine levels, and is only taking his 2
baseline antihypertensives.
Figure 1. Original adrenal computed tomography image revealing a 9-mm adrenal
adenoma measuring 2 Hounsﬁeld units (arrow). As the bladder was not visualized on
this scan, this was initially thought to be a pheochromocytoma.
Figure 3. Histologic appearance of our patient’s paraganglioma (original magniﬁcation
400). Tumor cells appear in a zellballen (clusters of chief cells) pattern and are
embedded in a ﬁbrous highly vascular network.
C.J. Neugarten et al. / Urology Case Reports 2 (2014) 189e190190Discussion
Bladder paragangliomas are rarely encountered in clinical
practice, and this case highlights the challenges in diagnosis and
treatment. Options for surgical management of these tumors
include transurethreal resection, partial cystectomy, and total cys-
tectomy, but there is controversy over whichmodality is preferred.1
This case underlines the difﬁculty in choosing a surgical approach,
as the exact location, extent, and ability to achieve a complete
resection endoscopically is not always apparent from imaging.
Furthermore, because these tumors can be highly vascularized and
can lead to hypertensive episodes whenmanipulated, resection can
be challenging and dangerous.1 Removal, both transurethral and
surgical, can be complicated by excessive bleeding and hyperten-
sion, even leading to hemorrhagic stroke.
Hypertensive crises are triggered bymicturition in 50%-70% cases.3
However, our patient’s hypertensive crises were unique in that they
were preceded by fecal urgency in concert with urinary urgency. This
phenomenonmay have been associatedwith bladder spasms, leading
to catecholamine release. He is also the only patient to our knowledge
to have had an incidental adrenalmass that complicated his diagnosis.
This underscores the importance of ruling out extra-adrenal disease
before proceeding with adrenalectomy in suspected pheochromocy-
toma, particularly if imaging ﬁndings are not conclusive for pheo-
chromocytoma. We recommend complete abdominopelvic axialFigure 2. Computed tomography angiography revealing a heterogeneous bladder
paraganglioma.imaging (as opposed to adrenal protocol only) in such a scenario.
MIBG scintigraphy can also be used to conﬁrm the diagnosis, but small
adrenal masses such as our patient’s are unlikely to register positive
on MIBG, even if the mass is a pheochromocytoma. Recently, MIBG is
largely being replaced by F-ﬂuoro-deoxy-2-glucose hybrid positron
emission tomographic in patients suspected of having catecholamine-
producing lesions.4
As many as 50% of paragangliomas are hereditary. If any family
members of a patient with a history of paraganglioma develop severe
hypertension that is not easily managed with medications, then ge-
netic testing for familial paraganglioma, neuroﬁbromatosis type 1, von
Hippel-Lindau disease, and multiple endocrine neoplasia type 2
should be considered. Lipid-rich pheochromocytomas have been re-
ported but are extremely rare. While most paragangliomas are
benign, the only reliable indicator of malignancy is the development
of metastasis, which occurs in up to 15% of tumors. Invasive growth,
recurrence, young age, and micturition attacks are also associated
with a poor prognosis.
Conclusion
Because paragangliomas can recur, long-term follow-up is
mandatory. However, there is no consensus on the duration and
frequency of such follow-up.1 It should include both monitoring of
hypertension and plasma or urine metanephrine levels. Some
advocate a conservative approach, including testing metanephrine
levels 10 days after operation and then annually for life.5 As long as
the patient remains asymptomatic and normotensive, screening
regimens can be discussed with the patient, and an informed de-
cision on the regimen can be made.
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